CORO7-PAM16

Across TCGA pan-cancer cohorts, CORO7-PAM16 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CORO7-PAM16 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CORO7-PAM16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CORO7-PAM16 expression acts as an unfavorable survival marker.

LUSC are the cancer types where CORO7-PAM16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.011	0.684	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

CORO7-PAM16–LUSC (OS)

Open the LUSC breakdown →